What Has Been the Growth of the Arthritis Monoclonal Antibodies Market So Far?
The arthritis monoclonal antibodies market has seen considerable growth due to a variety of factors.
• The market for arthritis monoclonal antibodies has seen robust growth in recent years. The market which was worth $58.09 billion in 2024 is projected to rise to $62.29 billion in 2025, indicating a compound annual growth rate (CAGR) of 7.2%.
The impressive growth during the previous years is linked to factors such as the escalating incidence of arthritis, enhanced understanding of arthritis monoclonal antibodies, the expansion of approved monoclonal antibodies for arthritis, governmental backing for research and development along with amplified investments from pharma corporations.
What Is the Forecasted Market Size and Growth Rate for The Arthritis Monoclonal Antibodies Market Size In The Coming Years?
The arthritis monoclonal antibodies market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, a robust growth is expected in the arthritis monoclonal antibodies market, with its size expected to reach $83.76 billion in 2029, representing a compound annual growth rate (CAGR) of 7.7%.
The anticipated growth can be linked to an increase in combination therapies, broader implications, patient choice, and elevated healthcare expenditure. Key trends set to shape the forecast period include biosimilars and biobetters, targeted treatments, home-based care, real-world data, concerns related to cost and access, and developments in drug delivery.
What Factors Are Driving Growth In The Arthritis Monoclonal Antibodies Market?
The global rise in arthritis cases is notably fuelling the expansion of the arthritis monoclonal antibody market. The Global RA Network highlighted in 2021 that arthritis and osteoarthritis affect over 350 million people across the world. Osteoarthritis emerges as the most prevalent form, with gout, fibromyalgia, and rheumatoid arthritis trailing behind. Projection from Arthritis Australia, a non-profit charitable entity, in February 2024 shows that the Australian arthritis population is set to surge from 4.11 million in 2025 to 5.39 million in 2040. This upsurge in arthritis cases is, therefore, a significant propellant for the arthritis monoclonal antibody market's growth.
What Are The Main Segments Of The Global Arthritis Monoclonal Antibodies Market?
The arthritis monoclonal antibodies market covered in this report is segmented –
1) By Drug: Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, Remsima
2) By Application: Rheumatoid Arthritis, Osteoarthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Fibromyalgia, Other Applications
3) By End-Use: Hospitals, Research Institutes, Other End-Users
Pre-Book The Arthritis Monoclonal Antibodies Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Arthritis Monoclonal Antibodies Market?
The progress in creating therapeutic monoclonal antibody products is proving to be crucial in advancing the arthritis monoclonal antibody market. Compared to small molecules and peptides, monoclonal antibodies show greater effectiveness in addressing arthritis. They are target-specific and exhibit high performance in disease management. This is highlighted by the increased release of monoclonal antibody drugs for arthritis in the market.
Who Are the Key Players In The Arthritis Monoclonal Antibodies Market?
Major companies operating in the arthritis monoclonal antibodies market include:
• Johnson & Johnson
• Hoffmann-La Roche Ltd.
• Novartis AG
• Pfizer Inc.
• AbbVie Inc.
• Amgen Inc.
• Genentech Inc.
• GlaxoSmithKline plc.
• AstraZeneca plc
• Bristol Myers Squibb
• Eli Lilly and Company
• Thermo Fisher Scientific Inc.
• Sanofi SA
• Daiichi Sankyo Company Ltd.
• Seattle Genetics
• Teva Pharmaceutical Industries Ltd.
• Shanghai Junshi Biosciences Co. Ltd.
• GenScript Biotech Corporation
• Sigma-Aldrich Co. LLC
• AbGenomics Corp.
• ADC Therapeutics SA
• Agensys Inc.
• Alexion Pharmaceuticals Inc.
• ALMAC Group Ltd.
• Ambrx Inc.
• Astellas Pharma Inc.
• Celgene Corporation
• Celldex Therapeutics Inc.
• Boehringer Ingelheim International GmbH
• Celltrion Inc.
• HanAll Biopharma Co. Ltd.
• Merck & Co. Inc.
• Mitsubishi Tanabe Pharma Corporation
• Regeneron Pharmaceuticals Inc.
• Samsung Bioepis Co. Ltd.
What Is The Most Dominant Region In The Arthritis Monoclonal Antibodies Market?
North America was the largest region in the arthritis monoclonal antibodies market in 2024. The regions covered in the arthritis monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
